Clinical trials: Resistant Major Depression
Major Depressive Disorder
Continuation Ketamine in Major Depression
As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with…
- Trial name
- NCT00548964
- Testing
- Lithium, Ketamine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- James Murrough
Major Depressive Disorder
Vagal Nerve Stimulation for Treatment Resistant Major Depression
The purpose of this study is to 1) explore whether vagal nerve stimulation (nVNS) using a hand- held non-invasive device (gammaCore™) works to treat depression and 2) to confirm gammaCore™'s safety profile.
- Trial name
- NCT04990687
- Testing
- gammaCore™
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Major Depressive Disorder
Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)
To confirm the safety and efficacy of the NCP System in treating patients in a nmajor depressive episode.
- Trial name
- NCT00533832
- Testing
- vagus nerve stimulation (VNS)
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Cyberonics, Inc.
Major Depressive Disorder
Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder
Assessing psychiatric and physiological co-morbidity in TRD and non-TRD patients
- Trial name
- NCT00229398
- Sponsor
- Sheba Medical Center
Major Depressive Disorder, Treatment Resistant Depression
Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression
This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual.
- Trial name
- NCT07528157
- Testing
- Personalized iTBS, Non-Personalized iTBS
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Stanford University
Major Depressive Disorder, Deep Brain Stimulation
The Efficacy and Prediction of Deep Brain Stimulation for Treatment-resistant Depression
Several open-label trials have shown the therapeutic promise of deep brain stimulation (DBS) targeted to striatal and surrounding capsular areas in treatment-resistant depression (TRD).
- Trial name
- NCT04530942
- Testing
- Deep brain stimulation(Active)
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Ruijin Hospital
Major Depressive Disorder, Treatment Resistant Depression
Low-Intensity Focused Ultrasound for Treatment-Resistant Depression
The Investigators are proposing to demonstrate safety and efficacy of LIFUP for treatment resistant major depressive disorder in a ten-patient pilot study.
- Trial name
- NCT06013384
- Testing
- Low-Intensity Focused Ultrasound Pulsation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder
A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)
The purpose of the study is to test whether oral 6(S)-5-MTHF (Deplin®) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (SSRIs).
- Trial name
- NCT00321152
- Testing
- 6(S)-5-MTHF (a Medical Food)
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Massachusetts General Hospital
Depression, Treatment Resistant
rTMS to Target Neural Connectivity and Rumination in Treatment-Resistant Depression
The goal of this clinical trial is to learn if Transcranial Magnetic Stimulation (TMS) to part of the brain called the ventromedial prefrontal cortex (VMPFC) can treat a symptom called rumination in adults with major depression…
- Trial name
- NCT06511544
- Testing
- Transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Major Depressive Disorder
5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
The investigators hypothesize that the administration of two widely available, naturally occurring dietary supplements, 5 hydroxytryptophan and creatine monohydrate, will reduce the severity of depression in individuals exposed…
- Trial name
- NCT02356107
- Testing
- 5-hydroxytryptophan and Creatine monohydrate
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Treatment Resistant Depression, Depressive Disorder
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
This is a randomized, placebo-controlled double-blind cross-over trial evaluating the safety, efficacy, daily functioning, and health-related quality of life of Subcallosal Cingulate Gyrus Deep Brain Stimulation (SCG DBS) for…
- Trial name
- NCT01801319
- Testing
- Libra Deep Brain Stimulation System
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abbott Medical Devices
Depressive Disorder, Major
Ketamine for Treatment Resistant MDD
This study aims to openly test the long-term safety, tolerability and effectiveness of repeated administration of IM/SC ketamine for treatment resistant MDD.
- Trial name
- NCT04021433
- Testing
- Ketamine
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Depressive Disorder, Major, Metabolic Syndrome X
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid…
- Trial name
- NCT00671515
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Joseph Calabrese, MD
Treatment Resistant Depression, Major Depressive Disorder
Predictors of Intravenous Ketamine Response in TRD
For patients with treatment-resistant depression (TRD), a single low dose of intravenous (IV) ketamine can help relieve symptoms as quickly as 24 hours later.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT05625555
- Testing
- Ketamine, Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abraham Nunes
Depressive Disorder, Treatment-Resistant
Adaptive tDCS for Treatment-Resistant MDD
This pilot study aims to investigate the potential role of transcranial direct current stimulation (tDCS) in the treatment of treatment-resistant major depressive disorder (MDD).
- Trial name
- NCT02942368
- Testing
- tDCS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.
- Trial name
- NARSAD (NCT03283670)
- Testing
- Nitrous Oxide 25%, Nitrous Oxide 50%
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder (MDD)
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium - Maintenance
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif XCS System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE-M (NCT07684794)
- Testing
- Motif XCS System
- Volunteers
- 10 people
- Sponsor
- Motif Neurotech, Inc.
Major Depressive Disorder, Treatment Resistant Depression
DBS for TRD With the Medtronic Summit RC+S
Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant.
- Trial name
- NCT04106466
- Testing
- Medtronic Summit RC+S DBS system
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Helen Mayberg, MD